Who is sponsoring NCT03389919?

NCT03389919 is sponsored by National Research Center for Hematology, Russia.

What drugs are being tested in NCT03389919?

Interventions in NCT03389919: MSC administration (intraosseal).

What condition does NCT03389919 study?

NCT03389919 studies Mesenchymal Stem Cell Transplantation.

Is NCT03389919 still recruiting?

NCT03389919 is currently status unknown. Last updated 4 January 2018.

Last reviewed 2018-01-04 · How we verify

NCT03389919

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT

Status unknown Phase 3 Last updated 4 January 2018

What this trial tests

Phase 3 trial testing MSC administration (intraosseal) in Mesenchymal Stem Cell Transplantation in 20 participants. Status unknown.

Timeline

1 January 2017

Primary endpoint
31 December 2020

31 December 2022

Quick facts

Lead sponsor	National Research Center for Hematology, Russia
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 January 2017
Primary completion	31 December 2020
Estimated completion	31 December 2022
Sites	1 location across Russia

Drugs / interventions tested

MSC administration (intraosseal) — full drug profile →

Conditions studied

Mesenchymal Stem Cell Transplantation — all drugs for Mesenchymal Stem Cell Transplantation →

Sponsor

National Research Center for Hematology, Russia — full company profile →

Who can join

18 and older, any sex, with Mesenchymal Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after allogeneic bone marrow (BM) transplantation. Since only few MSCs reach the BM after intravenous injection, MSCs were implanted into the iliac spine. Preliminary results suggest that MSCs participate in the restoration of niches for donor hematopoietic cells or have an immunomodulatory effect, preventing repeated rejection of the graft. Perhaps intraosseous implantation of MSCs contributes to the success of the second transplantation of hematopoietic stem cells and patient survival.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic Mesenchymal Stem/Stromal Cells: Value, Challenges and Optimization.
Najar M, Melki R, Khalife F, Lagneaux L, et al · · 2021 · cited 64× · PMID 35096805 · DOI 10.3389/fcell.2021.716853
Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?
Hamdan H, Hashmi SK, Lazarus H, Gale RP, et al · · 2021 · cited 11× · PMID 32854985 · DOI 10.1016/j.blre.2020.100742
Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells.
Petinati N, Drize N, Sats N, Risinskaya N, et al · · 2018 · cited 9× · PMID 29760731 · DOI 10.1155/2018/6495018

Verify or expand the search:

Other National Research Center for Hematology, Russia trials

Trials by the same sponsor.

NCT06721598 — An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproli · not yet recruiting
NCT06705530 — A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphop · Phase 1, PHASE2 · completed
NCT06237192 — MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients · NA · recruiting
NCT06188676 — Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunother · Phase 3 · recruiting
NCT05158608 — Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03389919 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Research Center for Hematology, Russia
Last refreshed: 4 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03389919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing